相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prenatal therapy in transient abnormal myelopoiesis: a systematic review
J. A. Tamblyn et al.
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION (2016)
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan
Takashi Taga et al.
PEDIATRIC BLOOD & CANCER (2016)
Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities
Kimihiko Banno et al.
CELL REPORTS (2016)
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network
Aurelie Caye et al.
NATURE GENETICS (2015)
Stem and progenitor cell dysfunction in human trisomies
Binbin Liu et al.
EMBO REPORTS (2015)
Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis
Myoung Ja Park et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Reduced Intensity Conditioning in Allogeneic Stem Cell Transplantation for AML With Down Syndrome
Hideki Muramatsu et al.
PEDIATRIC BLOOD & CANCER (2014)
Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome
Johann K. Hitzler et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome
Tsutomu Toki et al.
BLOOD (2013)
Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder
Yehudit Birger et al.
BLOOD (2013)
Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome
Sergey I. Nikolaev et al.
BLOOD (2013)
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia
Irene Roberts et al.
BLOOD (2013)
Blast Cell Deficiency of CD11a as A Marker of Acute Megakaryoblastic Leukemia and Transient Myeloproliferative Disease in Children with and Without Down Syndrome
Heidrun Boztug et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
The landscape of somatic mutations in Down syndrome-related myeloid disorders
Kenichi Yoshida et al.
NATURE GENETICS (2013)
Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome
Takashi Taga et al.
BLOOD (2012)
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971
April D. Sorrell et al.
CANCER (2012)
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome
Sebastien Malinge et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21
Anindita Roy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells
Stella T. Chou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells
Glenn A. MacLean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia
Kate A. Alford et al.
BLOOD (2011)
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971
Alan S. Gamis et al.
BLOOD (2011)
Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome
Kate A. Alford et al.
BLOOD (2010)
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis
Jan-Henning Klusmann et al.
GENES & DEVELOPMENT (2010)
Hematopoietic defects in the Ts1Cje mouse model of Down syndrome
Catherine L. Carmichael et al.
BLOOD (2009)
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Sebastien Malinge et al.
BLOOD (2009)
ERG Is a Megakaryocytic Oncogene
Samira Salek-Ardakani et al.
CANCER RESEARCH (2009)
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome
Gina Kirsammer et al.
BLOOD (2008)
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations
Oliver Tunstall-Pedoe et al.
BLOOD (2008)
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
Jan-Henning Klusmann et al.
BLOOD (2008)
Risk factors for early death in neonates with Down syndrome and transient leukaemia
Hideki Muramatsu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML
H. Hasle et al.
LEUKEMIA (2008)
Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome:: an iBFM-SG study
Erik Forestier et al.
BLOOD (2008)
Haematology of down syndrome
David Webb et al.
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION (2007)
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
Gita V. Massey et al.
BLOOD (2006)
Cancer incidence of persons with Down syndrome in Finland: A population-based study
K Patja et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
A Rao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Acute promyelocytic leukemia and constitutional trisomy 21
C Kurkjian et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Transcription factor GATA-1 and Down syndrome leukemogenesis
Andrew G. Muntean et al.
LEUKEMIA & LYMPHOMA (2006)
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials
U Creutzig et al.
LEUKEMIA (2005)
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
U Creutzig et al.
LEUKEMIA (2005)
Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts
C Langebrake et al.
KLINISCHE PADIATRIE (2005)
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21
L Rainis et al.
BLOOD (2003)
GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome
JK Hitzler et al.
BLOOD (2003)
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
H Hasle et al.
LEUKEMIA (2003)
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
J Wechsler et al.
NATURE GENETICS (2002)
Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric oncology group study
F Al-Kasim et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
CM Zwaan et al.
BLOOD (2002)
Risks of leukaemia and solid tumours in individuals with Down's syndrome
H Hasle et al.
LANCET (2000)
分享论文
